CCG-100602 | 1207113-88-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: CCG-100602
• 英文别名: 1-[3,5-bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)piperidine-3-carboxamide
• CAS: 1207113-88-9
• 化学式: C₂₁H₁₇ClF₆N₂O₂
• 分子量: 478.822
• InChiKey: MOQCFMZWVKQBAP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  CCG-100602 、 Lithium aluminium hydride 、 水 、 sodium hydroxide 在 四氢呋喃 、 crude material 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以to afford 14 mg of title compound as a yellow oil的产率得到N-((1-(3,5-bis(trifluoromethyl)benzyl)piperidin-3-yl)methyl)-4-chloroaniline
  参考文献：
  名称：

  METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION

  摘要：

  本发明提供了抑制Rho GTPase家族成员的方法、组合物和试剂盒。具体来说，本发明提供了抑制RhoA和/或RhoC转录信号的方法、组合物和试剂盒。本发明可用于治疗Rho介导的疾病状态（例如肿瘤转移、炎症、炎症性疾病）、Rho介导的生物条件以及细胞信号研究。

  公开号：

  US20120252792A1
• 作为产物：
  描述：

  1-BOC-哌啶-3-羧酸 在 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 CCG-100602
  参考文献：
  名称：

  Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c01950

文献信息

• CELL AGGREGATION PROMOTING AGENT
  申请人：Kaneka Corporation

  公开号：EP3733837A1

  公开（公告）日：2020-11-04

  The present invention is directed to providing a means for appropriately controlling the size of cell aggregates without relying on mechanical/physical means. Specifically, the present invention relates to a cell aggregation promoter for use in suspension culture of cells, comprising an SRF inhibitor. The present invention also relates to a method for producing cell aggregates, comprising a step of culturing cells in suspension in a culture medium comprising an SRF inhibitor.

  本发明旨在提供一种不依赖机械/物理手段而适当控制细胞聚集体大小的方法。具体地说，本发明涉及一种用于细胞悬浮培养的细胞聚集促进剂，包括一种 SRF 抑制剂。本发明还涉及一种生产细胞聚集体的方法，包括在含有 SRF 抑制剂的培养基中培养悬浮细胞的步骤。
• Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423
  作者：Chris R. Evelyn、Jessica L. Bell、Jenny G. Ryu、Susan M. Wade、Andrew Kocab、Nicole L. Harzdorf、H.D. Hollis Showalter、Richard R. Neubig、Scott D. Larsen

  DOI：10.1016/j.bmcl.2009.11.056

  日期：2010.1

  We recently identified bis(amide) CCG-1423 (1) as a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. An initial structure-activity relationship study focusing on bioisosteric replacement of the amides and conformational restriction identified two compounds, 4g and 8, with improved selectivity for inhibition of RhoA/C-mediated gene transcription and attenuated cytotoxicity relative to 1. Both compounds were also capable of inhibiting cell invasion with equal efficacy to 1 but with less attendant cytotoxicity. (C) 2009 Elsevier Ltd. All rights reserved.
• CELL AGGREGATION PROMOTER
  申请人：KANEKA CORPORATION

  公开号：US20210062159A1

  公开（公告）日：2021-03-04

  The present invention is directed to providing a means for appropriately controlling the size of cell aggregates without relying on mechanical/physical means. Specifically, the present invention relates to a cell aggregation promoter for use in suspension culture of cells, comprising an SRF inhibitor. The present invention also relates to a method for producing cell aggregates, comprising a step of culturing cells in suspension in a culture medium comprising an SRF inhibitor.
• [EN] METHODS AND COMPOSITIONS FOR INHIBITING RHO-MEDIATED DISEASES AND CONDITIONS<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR INHIBER DES MALADIES ET DES ÉTATS À MÉDIATION PAR RHO
  申请人：UNIV MICHIGAN

  公开号：WO2011035143A2

  公开（公告）日：2011-03-24

  The invention provides methods, compositions, and kits for the inhibition of members of the Rho GTPase family. Specifically, the invention provides methods, compositions and kits for the inhibition of RhoA and/or RhoC transcriptional signalling. The invention finds use in treatment of Rho-mediated disease states (e.g., tumor metastasis, inflammation, inflammatory disease), Rho-mediated biological conditions, and in cell signaling research.